Is androgen production in association with immune system activation potential evidence for existence of a functional adrenal/ovarian autoimmune system in women?

Reproductive Biology and Endocrinology

David H Barad²  Ho-Joon Lee³  Emanuela Lazzaroni³  Aya Shohat-Tal³  Vitaly A Kushnir³  Andrea Weghofer¹  Norbert Gleicher² 

[1] Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University Vienna, Vienna 1090, Austria;Foundation for Reproductive Medicine, New York, NY 10021, USA;Center for Human Reproduction, New York, NY 10021, USA

关键词: In Vitro Fertilization;    Autoimmunity;    Ovarian Reserve;    Testosterone;    Androgens;   

Others  :  811399
DOI  :  10.1186/1477-7827-11-58

 received in 2013-03-22, accepted in 2013-06-24,  发布年份 2013

【 摘 要 】

Background

Low functional ovarian reserve (FOR) is at all ages associated with low testosterone (T) levels. Causes are, however, unknown. We, therefore, investigate whether androgens with low FOR are associated with non-specific immune system activation.

Methods

322 infertile women with low and normal FOR (controls) were assessed with a broadly based immune profile, which in previous studies has proven effective in differentiating infertile patients with and without immune system activation. Patients were either immune-positive (greater than or equal to one positive tested parameter) or immune negative (no positive test). 135 suffered from prematurely diminished FOR (POA/OPOI; < age 38), 155 from physiologic diminished FOR due to age (DOR; > age 40), and 32 were controls (< age 38 with normal age-specific FOR). Prevalence of immune-positive vs. negative was assessed in all 3 patient groups.

Results

Women with immune abnormalities, overall, demonstrated higher total T (TT, P = 0.004) and free T (FT, P < 0.001) levels than those without. The three clinical and two immunologic-defined patient groups demonstrated significant statistical interaction in mean TT (P = 0.008), with mean TT and FT in women with positive immune findings being significantly higher in control than in POA/OPOI and physiologic DOR patients (all 4 differences P < 0.001). No such differences between the three groups were seen in women without immune abnormalities.

Conclusions

In this study we used a definition of immune-positivity, which favors sensitivity over specificity, resulting in significant numbers of false-positives but likely only few false-negatives. The study allows suggesting the possibility of an immune system-derived androgen-production factor (APF), which maintains normal androgen levels but is deficient in women with low FOR and immune system inactivity. Existence of such an APF would suggest the presence of a still unknown functional adrenal autoimmune system.

【 授权许可】

   
2013 Gleicher et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ledger W: Clinical utility of measurements of anti-Müllerian hormone in reproductive endocrinology. J Clin Endocinol Metab 2010, 95:5144-5154.
• [2]Gleicher N, Weghofer A, Barad DH: Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol 2011, 9:23. BioMed Central Full Text
• [3]Kevenaar ME, Meerasahib MF, Kramer P, van de lang-Born BM, de Jong FH, Groome NP, Themmen AP, Visser JA: Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006, 147:3228-3234.
• [4]Sen A, Hammes SR: Granulosa-cell specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol 2010, 24:1393-1403.
• [5]Frattarelli JL, Gerber MD: Effects of androgen levels on in vitro fertilization cycles. Fertil Steril 2006, 86:51-57.
• [6]Hossein Rashidi B, Hormoz B, Shahrokh Tehraninejad E, Shariat M, Mahdavi A: Testosterone and dehydroepiandrosterone sulphate levels and IVF/ICSi results. Gynecol Endocrinol 2009, 25:194-198.
• [7]Gleicher N, Barad DH: Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol 2011, 9:67. BioMed Central Full Text
• [8]Gleicher N, Kim A, Weghofer A, Shohat-Tal A, Lazzaroni E, Lee HJ, Kushnir V, Barad DH: Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). J Assist Reprod Genet 2013, 30:49-62.
• [9]Gleicher N, Kim A, Weghofer A, Shohat-Tal A, Lazzaroni E, Lee HJ, Kushnir V, Barad DH: Hypoandrogenism in association with diminished functional ovarian reserve. Hum Reprod 2013, 28:1084-1091.
• [10]Zaleteal K, Gaberšček S: Hashimoto’s thyroiditis: From gene to disease. Curr Genomics 2011, 12:576-588.
• [11]Ando T, Davies T: Monoclonal antibodies to the thyrotropin receptor. Clin Dev Immunol 2005, 12:137-143.
• [12]Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spandoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
• [13]Gleicher N, Barad D, Weghofer A: Functional autoantibodies, a new paradign in autoimmunity? Autoimmune Rev 2007, 7:42-45.
• [14]Weghofer A, Brill H, Feichtinger R, Barad D, Gleicher N: Does autoimmunity play a role in the pathophysiology of premature ovarian ageing? Reprod Biomed Online 2008, 6:830-834.
• [15]Gleicher N, Weghofer A, Oktay K, Barad DH: Is the immunological noise of abnormal autoimmunity an independent risk factor for premature ovarian aging? J North Am Menopause Soc 2009, 16:760-764.
• [16]Barad DH, Weghofer A, Gleicher N: Age-specific levels of basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol 2007, 109:1404-1410.
• [17]Barad DH, Weghofer A, Gleicher N: Utility of age-specific serum anti-Müllerian hormone concentrations. Reprod Biomed Online 2011, 22:284-291.
• [18]Gleicher N, Weghofer A, Barad DH: Cutting edge assessment of the impact of autoimmunity on female reproductive success. J Autoimmun 2012, 38:J74-J80.
• [19]Cervera R, Balasch J: Bidirectional effects of autoimmunity and reproduction. Hum Reprod Update 2008, 14:359-366.
• [20]Gleicher N, Weghofer A, Barad DH: A pilot study of premature ovarian senescence: II. Different genotype and phenotype for genetic and autoimmune etiologies. Fertil Steril 2009, 91:1707-1711.
• [21]Gleicher N, Weghofer A, Lee IH, Barad DH: FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance. PLoS One 2012, 5(12):e15303.
• [22]Gleicher N, Weghofer A, Lee IH, Barad DH: Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS One 2011, 6(4):e18781.
• [23]Fijak M, Schneider E, Klug J, Bhushan S, Hackstein H, Schuler G, Wygrecka M, Gromoll J, Meinhardt A: Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: Evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol 2011, 186:5162-5172.
• [24]Corrales JJ, Almeida M, Cordero M, Martin-martin L, Méndez C, Miralles JM, Orfao A: Enhanced immunological response by dendritic cells in male hypogonadism. Eur J Clin Invest 2012.
• [25]Roberts M, Peters A: Is testosterone immunosuppressive in a condition-dependent manner? An experimental test in blue tits. J Exp Biol 2009, 212(Pt 12):1811-1818.
• [26]Brozzetti A, Marzotti S, La Torre D, Bacosi ML, Morelli S, Bini V, Ambrosi B, Giordano R, Perniola R, De Bellis A, Betterle C, Falorni A, on behalf of the Italian Addison Network: Autoantibody responses in autoimmune ovarian insufficiency and in Addison’s disease are IgG1 dominated and suggest a predominant, but not exclusive, Th 1 type of response. Eur J Endocrinol 2010, 163:309-317.
• [27]Albertini DF: Searching for answers to the riddle of ovarian aging. J Assist Reprod Genet 2012, 29:577-578.
• [28]Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX: Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in large-scale Chinese population. BJOG 2009, 116:1633-1639.
• [29]Van Gelderen CJ, Gomes dos Santos MI: Polycystic ovarian syndrome. Evidence for an autoimmune mechanism in some cases. J Reprod Med 1993, 38:381-386.
• [30]Hefler-Frischmuth K, Walch K, Huebl W, Baumuehlner K, Tempfer C, Hefler L: Serologic markers of autoimmunity in women with polycystic ovary syndrome. Fertil Steril 2010, 93:2291-2294.
• [31]González F, Sia CL, Stanczyk FZ, Blair HE, Krupa ME: Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. Endocrine 2012, 42:726-735.
• [32]Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, Filippi S, Logiodice F, Carini M, Nesi G, Gacci M, Piccinni MP, Adirii L, Maggi M: Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012, 214:31-43.
• [33]Gleicher N, Weghofer A, Barad DH: The role of androgens in follicle maturation and ovulation induction: friend of foe of infertility treatment? Reprod Biol Endocrinol 2011, 9:116. BioMed Central Full Text
• [34]Jacobs B, Papewalis C, Ehlers M, Schott M: Endocrine organs under the control of the immune system: potential implications for cellular therapies. Horm Metab Res 2010, 42:912-917.
• [35]Tagoe CE, Zezon A, Khattri S: Rheumatic manifestations of autoimmune thyroid disease: the other autoimmune disease. J Rheumatol 2012, 39:1125-1129.
• [36]Betterle C, Morlin L: Autoimmune Addison’s disease. Endocr Dev 2011, 20:161-172.
• [37]Chen S, Sawicka J, Betterle C, Powell M, Prentice L, Volpato M, Rees Smith B, Furmaniak J: Autoantbodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison’s disease, and premature ovarian failure. J Clin Endocrinol Metab 1996, 81:1871-1876.
• [38]Nigam R, Bhatia E, Miai D, Yu L, Brozzetti A, Eisenbarth GS, Falorni A: Prevalence of adrenal antibodies in Addison’s disease among north Indian Caucasians. Clin Endocrinol 2003, 59:593-598.
• [39]Gleicher N, Barad DH: Gender as risk factor for autoimmune diseases. J Autoimmun 2007, 28:1-6.
• [40]Sen A, Kushnir VA, Barad DH, Gleicher N: Endocrine autoimmune diseases and female infertility. Nature Endocrin Rev 2013. in press